On July 25, 2019, Health Canada released an updated version of the Guidance Document: The Management of Drug Submissions and Applications. The updates follow from an earlier consultation and reflect updated processes and procedures related to filing a submission or application to Health Canada. These changes include a broad reorganization of information, an added section on classification of a therapeutic product (e.g., as a drug, biologic, a medical device or a combination product), and modified times to respond to a clarification request during a scientific review, which are based on the type and performance standard of the submission/application.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada launches new Clinical Trial Search Portal and publishes updated guidance
As part of its efforts to modernize clinical trials and enhance transparency (see our previous article), Health Canada has launched a new Clinical Trial Search Portal, replacing the Clinical Trials Da...Read More -
New regulatory amendments formalize updates to the drug and medical device shortages framework
On June 17, 2026, Health Canada published the Regulations Amending Certain Regulations Made Under the Food and Drugs Act (Shortages and Discontinuation of Sale of Drugs and Medical Devices).Read More -
Medical device updates: MDEL modernization, Class III & IV licence applications, and MDD performance reports
As we previously reported, Health Canada announced that the Phase II amendments to the Medical Devices Regulations (MDR) regarding medical device establishment licences (MDELs) will come into force De...Read More
